CDH2 and chronic myelogenous leukemia, BCR-ABL1 positive: When interrupted the N-cadherin-mediated adhesion of chronic myeloid leukemia (CML) cells to BMSCs, the tumor cells gained sensitivity toward imatinib treatment (Zhang et al., 2013).